June 12, 2024

Pfizer has announced that our Phase 3 CIFFREO study evaluating fordadistrogene movaparvovec did not meet its primary endpoint of improvement in motor function among ambulatory boys 4 to 7 years of age treated with this gene therapy compared to placebo. Key secondary endpoints also did not show a significant difference between participants treated with fordadistrogene movaparvovec and placebo.

We are deeply disappointed that the data do not reflect the results that were hoped for and recognize this is a significant setback for the DMD community that is awaiting improved treatment options. More detailed results will be shared with the scientific and patient communities at upcoming medical and patient advocacy meetings. We are hopeful that these efforts will play a role in informing and continuing to improve the development of future DMD treatments.

It has long been our goal to provide much-needed treatment options for boys living with DMD as we've worked closely in partnership with the DMD and scientific community for more than 10 years, and we will share additional information on these results as they become available. In the meantime, we would be remiss if we did not recognize and thank the participants, their supportive families, and the trial investigators for their incredible dedication and contributions to this very important research.

Sincerely,
The Pfizer DMD gene therapy team